Oncotarget

Research Papers:

Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma

Jing-hua Wang, Liang Wang, Cheng-cheng Liu, Zhong-jun Xia, Hui-qiang Huang, Tong-yu Lin, Wen-qi Jiang and Yue Lu _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:29092-29101. https://doi.org/10.18632/oncotarget.8647

Metrics: PDF 2340 views  |   HTML 1497 views  |   ?  


Abstract

Jing-hua Wang1,2,3,*, Liang Wang1,2,3,*, Cheng-cheng Liu1,2,3,*, Zhong-jun Xia1,2,3, Hui-qiang Huang2,3,4, Tong-yu Lin2,3,4, Wen-qi Jiang2,3,4, Yue Lu1,2,3

1Department of Hematologic Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People’s Republic of China

2State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, People’s Republic of China

3Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, People’s Republic of China

4Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People’s Republic of China

*These authors contributed equally to this work

Correspondence to:

Yue Lu, email: yuelv304@yahoo.com

Keywords: extranodal NK/T-cell lymphoma, gemcitabine, oxaliplatin, pegaspargase, adverse effects

Received: November 02, 2015     Accepted: March 18, 2016     Published: April 08, 2016

ABSTRACT

Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive neoplasm with a poor outcome. Asparaginase-based regimens are recommended for patients with advanced-stage or relapsed/refractory ENKTL. We retrospectively investigated the efficacy and toxicity of combined gemcitabine, oxaliplatin, and pegaspargase (P-gemox) in these patients. A total of 35 patients with newly diagnosed stage III–IV, relapsed or refractory ENKTL were treated with 2 to 8 cycles of P-gemox: gemcitabine (1250 mg/m2) and oxaliplatin (85 mg/m2) injected intravenously and pegaspargase (2500 IU/m2) injected intramuscularly on day 1 and repeated every 2 weeks. Upon completion of treatment, the overall response rate was 80.0%, with a complete response in 51.4% of patients. The 1-, 2- and 3- year progression-free survival rates were 45.0%, 38.6% and 38.6%, and overall survival rates were 76.8%, 64.7% and 64.7%, respectively. Patients who attained a complete response showed better progression-free survival than those without a complete response (p = 0.01). The major adverse effects were hematologic toxicity and liver dysfunction. Grade 3/4 leucopenia and neutropenia occurred in 40.0% of patients. No treatment-related deaths occurred. These results indicate the P-gemox regimen is a safe and effective treatment for patients with newly diagnosed advanced-stage or relapsed/refractory ENKTL. We anticipate future prospective trials will confirm the efficacy.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 8647